LL-37: Natural Antimicrobial for Gut Health

Introduction

Your gut is home to trillions of microorganisms -- some beneficial, some potentially harmful. The balance between them significantly affects your health, and your immune system is constantly working to maintain that balance. At the front lines of this defense is LL-37, the only cathelicidin antimicrobial peptide produced by humans.

LL-37 is not an antibiotic you take from a bottle. It is a 37-amino-acid peptide that your own body produces, released by neutrophils, macrophages, and epithelial cells as a first-line defense against microbial invasion. Researchers are exploring whether supplementing with synthetic LL-37 can support gut health, particularly in cases of microbial imbalance or biofilm-associated infections.

In this article, you will learn how LL-37 interfaces with gut microbial health, why its antimicrobial and immunomodulatory properties are relevant to the gut, and how FixMyT can help you understand whether microbial imbalance may be affecting your metabolic health.

Understanding the Gut: The Signal of Your Metabolism

The Gut node in the FixMyT metabolic tree occupies Level 2, downstream from Mitochondria and upstream of the Liver and Serotonin pathways. The subtitle "Signal" reflects the gut's role as a hormonal signaling organ, but there is another dimension: the gut is also an interface with the microbial world.

The Gut node encompasses:

• Minimizing endotoxin: Controlling bacterial byproducts that trigger inflammation
• Microbial balance: Maintaining healthy ratios between beneficial and harmful organisms
• Barrier integrity: Keeping microbes and their products where they belong
• Immune regulation: Appropriate immune responses to microbial signals

When microbial balance is disrupted -- whether through pathogenic overgrowth, biofilm formation, or small intestinal bacterial overgrowth (SIBO) -- the consequences extend throughout the metabolic cascade. The liver receives gut blood laden with endotoxin, serotonin production is disrupted, and systemic inflammation rises.

The challenge with gut infections and dysbiosis is that conventional antibiotics can cause collateral damage to beneficial bacteria. LL-37 offers a different approach: a targeted antimicrobial that your immune system already uses.

What Is LL-37?

LL-37 is the only human cathelicidin antimicrobial peptide. Its name refers to the two leucine (L) residues at its N-terminus and its length of 37 amino acids. It is derived from the C-terminus of the 18 kDa human cationic antimicrobial protein (hCAP18) and is produced by various immune and epithelial cells.

Key characteristics:

• Origin: Naturally occurring human antimicrobial peptide
• Classification: Cathelicidin / Host defense peptide
• Length: 37 amino acids
• Charge: +6 at physiological pH (cationic)
• Research status: Phase 2 trials ongoing for chronic wounds and infections

LL-37 is typically administered via subcutaneous injection (100-300 mcg, 1-2x daily) or topically for wound applications. Intranasal delivery has been explored for sinus infections. It is currently a research compound and is not FDA-approved.

What makes LL-37 particularly interesting is its dual function: it is both antimicrobial and immunomodulatory. It kills pathogens directly while also regulating immune responses -- a combination that synthetic antibiotics cannot match.

For complete technical details, see the full LL-37 profile on PepGuide.

How LL-37 Supports Gut Function

LL-37 operates through multiple mechanisms relevant to gut health and microbial balance.

1. Broad-Spectrum Antimicrobial Activity

LL-37 demonstrates activity against gram-positive bacteria (including S. aureus, Streptococcus, MRSA), gram-negative bacteria (E. coli, P. aeruginosa, Klebsiella), fungi (Candida, Aspergillus), and even some viruses.

The mechanism involves disrupting microbial membranes. LL-37's cationic charge attracts it to the negatively charged bacterial membrane, where it forms pores or creates a "carpet-like" coverage that causes cell death. Importantly, human cell membranes have different composition and are not affected.

2. Anti-Biofilm Activity

One of LL-37's most relevant properties for gut health is its ability to prevent and disrupt biofilms. Biofilms are protective matrices that bacteria form around themselves, making them resistant to antibiotics and immune clearance.

Research published in Infection and Immunity (2008) demonstrated that LL-37 prevents biofilm formation and can disrupt established biofilms. This is relevant for conditions like SIBO and chronic gut infections where biofilms may be protecting pathogenic organisms.

3. Immunomodulation

Beyond direct killing, LL-37 modulates immune responses:

• Chemotaxis: Attracts immune cells to infection sites
• Cytokine modulation: Balances inflammatory responses
• Enhanced phagocytosis: Improves immune cell function
• Activation of innate immune pathways via TLR signaling

This immunomodulatory function means LL-37 supports the immune system's natural function rather than replacing it.

4. Endotoxin Neutralization

LL-37 can bind and neutralize bacterial endotoxin (LPS), the inflammatory molecule released by gram-negative bacteria. Since minimizing endotoxin is a core function of the Gut node in the FixMyT framework, this is directly relevant to metabolic health.

What Real People Are Saying

LL-37 has attracted interest in the peptide research community, particularly for chronic or biofilm-associated infections:

"Used LL-37 as part of a SIBO protocol after multiple rounds of antibiotics failed. The theory was biofilms protecting the bacteria. Added LL-37 to the antibiotic rotation and finally saw improvement in breath test numbers. Whether it was the LL-37 specifically or the combination, something worked." — u/sibo_fighter on r/SIBO

"Running LL-37 for chronic sinusitis that extended to gut issues (post-nasal drip affecting digestion). The intranasal application helped the sinus symptoms, and interestingly my gut symptoms improved as well. Connection between sinus microbiome and gut maybe?" — u/chronic_sinus on r/Peptides

"The biofilm aspect is what interested me. Candida overgrowth that antifungals kept reducing but never eliminating. LL-37 plus antifungal seems more effective than antifungal alone. Still early but promising." — u/candida_research on r/Candida

These are individual experiences from personal research. LL-37's immunomodulatory effects mean individual responses can vary based on baseline immune function.

Monitoring Your Gut Health with FixMyT

Understanding gut microbial health requires looking at symptoms and metabolic context. FixMyT provides a framework for assessing the Gut node and its downstream effects.

The FixMyT symptoms quiz identifies markers relevant to microbial imbalance:

• Bloating and gas (may indicate fermentation from microbial overgrowth)
• Food sensitivities (can be triggered by microbial metabolites)
• Brain fog (often gut-derived, linked to endotoxin)
• Fatigue (metabolic burden from immune activation)

The visual metabolic tree shows how the Gut connects to the Liver (receives gut blood including microbial products) and Serotonin (90% produced in the gut, affected by microbial balance). Addressing microbial imbalance can have effects throughout this cascade.

If you are considering LL-37, understanding your baseline is essential. FixMyT helps you determine whether gut-level microbial issues are contributing to your symptoms.

Research and Considerations

LL-37's research base is extensive for antimicrobial applications, though gut-specific studies are still developing:

What the evidence supports:

• Broad-spectrum antimicrobial activity (well-established)
• Anti-biofilm effects (documented in vitro and in vivo)
• Immunomodulatory properties (multiple receptor interactions)
• Endotoxin neutralization capability

What needs more research:

• Gut-specific applications and dosing
• Optimal delivery methods for intestinal targets
• Long-term safety with repeated use
• Comparison to conventional antimicrobial therapies

An important consideration is that LL-37 is dysregulated in certain conditions -- elevated in rosacea and psoriasis, for example. This highlights that balance is important; neither deficiency nor excess is ideal. For gut applications, systemic levels would likely remain within normal ranges.

Disclaimer

This article is for educational and research purposes only. LL-37 is not approved for human use by the FDA or other regulatory agencies. Nothing in this article constitutes medical advice or a recommendation to use any substance.

Gut infections and microbial imbalances require proper medical evaluation. If you are experiencing persistent digestive symptoms, consult with a healthcare provider to identify the underlying cause before considering any interventions.

Individual responses vary significantly, particularly with immunomodulatory compounds. The information here reflects current research as of the publication date and may evolve.

Learn More

• Full LL-37 Profile on PepGuide - Complete technical details and mechanisms
• BPC-157: The Gut Healing Peptide - Complementary tissue repair
• KPV for Gut Inflammation - Anti-inflammatory approach
• FixMyT Metabolic Assessment - Understand your gut and metabolic baseline

References

1. Vandamme D, et al. "A comprehensive summary of LL-37, the factotum human cathelicidin peptide." Cellular Immunology. 2012;280(1):22-35. doi:10.1016/j.cellimm.2012.11.009

2. Overhage J, et al. "Human host defense peptide LL-37 prevents bacterial biofilm formation." Infection and Immunity. 2008;76(9):4176-4182. doi:10.1128/IAI.00318-08

3. Fabisiak A, et al. "LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity." Pharmacological Reports. 2016;68(4):802-808.

4. Heilborn JD, et al. "The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds." Journal of Investigative Dermatology. 2003;120(3):379-389.

5. Antimicrobial Peptide Research. "Host Defense Peptides in Clinical Development: LL-37 and Beyond." Frontiers in Immunology. 2025.